Audiomedica.com
First-Line Pembrolizumab Boosts Survival in PD-L1-Positive Advanced Lung Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:11:00
- Mas informaciones
Informações:
Sinopsis
Audio Journal of Oncology, January 2, 2017 COPENHAGEN—Patients with metastatic non-small cell lung cancers (NSCLC) expressing the programmed cell-death ligand 1 (PD-L1) protein responded better to initial treatment with the anti-PD-L1 immunotherapy pembrolizumab—and lived longer with fewer toxicities—than to standard …161209 Audio Journal of Oncology RECK PRODUCTION MASTER
